mark
anniversari
approv
zidovudin
azt
first
hivaid
therapi
sinc
eighti
antivir
drug
receiv
fda
approv
half
treat
hiv
infect
provid
retrospect
analysi
approv
antivir
drug
includ
therapeut
major
chronic
infect
hepat
b
c
herp
virus
last
thirti
year
time
drug
approv
treat
acut
viral
infect
mainli
influenza
analysi
approv
antivir
drug
base
molecular
class
mode
action
show
larg
major
small
molecul
directact
agent
oppos
protein
peptid
oligonucleotid
hosttarget
therapi
addit
approv
combin
therapi
acceler
last
five
year
also
provid
prospect
studi
futur
potenti
antivir
therapi
base
current
clinic
research
pipelin
across
pharmaceut
industri
compar
past
drug
approv
current
clinic
candid
hint
futur
evolut
antivir
therapi
reveal
antivir
medicin
often
discov
overal
work
help
forecast
futur
trend
innov
field
antivir
research
develop
field
antivir
research
taken
new
dimens
sinc
global
spread
human
immunodefici
viru
hiv
caus
acquir
immun
defici
syndrom
aid
epidem
unpreced
effort
academ
pharmaceut
laboratori
develop
new
effect
antivir
therapi
effort
led
advanc
basic
scienc
mani
therapeut
breakthrough
includ
develop
inhibitor
target
hiv
virus
review
analyz
antivir
therapeut
market
sinc
approv
zidovudin
retrovir
basi
clinic
indic
molecular
size
small
versu
larg
mode
action
molecular
target
use
combin
therapeut
agent
also
report
antivir
therapeut
current
clinicalstag
evalu
goal
compar
current
research
past
approv
predict
potenti
trend
chang
antivir
medicin
work
also
help
understand
drive
forc
behind
innov
success
antivir
research
inform
antivir
drug
evalu
gather
directli
food
drug
administr
fda
drug
databas
http
wwwaccessdatafdagovscriptscderdaf
monthli
approv
report
januari
decemb
scan
creat
exhaust
list
antivir
medic
approv
unit
state
period
narrow
focu
novel
therapeut
agent
gener
drug
exclud
list
identifi
agent
tent
approv
gener
drug
product
readi
approv
patent
exclus
protect
refer
list
drug
product
expir
fda
issu
tent
approv
letter
delay
final
approv
gener
drug
product
patent
exclus
issu
resolv
tent
approv
letter
therefor
provid
mean
screen
gener
equival
evalu
next
drug
consid
explicitli
antivir
pharmacokinet
enhanc
like
cobicistat
exclud
result
subset
drug
list
condens
restrict
drug
submit
either
class
new
molecular
entiti
nme
class
new
combin
elimin
approv
relat
formul
chang
extendedreleas
version
previous
approv
drug
http
www
fdagovdownloadsaboutfdacentersoffic
defin
nme
drug
contain
activ
moieti
never
approv
fda
market
us
drug
epivir
receiv
approv
novel
indic
first
hiv
later
hepat
b
viru
hbv
approv
includ
separ
entri
final
list
consist
uniqu
antivir
drug
approv
catalog
use
follow
characterist
approv
antivir
drug
ten
discontinu
withdrawn
mark
tabl
four
criteria
establish
includ
drug
candid
list
antivir
develop
evalu
drug
candid
requir
human
trial
phase
therapeut
agent
ie
vaccin
submit
us
fda
list
clinicaltrialsgov
activ
develop
mean
clinic
compani
updat
evid
past
year
initi
list
drug
candid
clinic
develop
glean
research
pipelin
inform
avail
compani
websit
larg
small
compani
activ
antivir
drug
develop
space
next
recent
publish
review
cover
drug
develop
differ
virus
drug
class
screen
eg
salazar
et
al
final
list
supplement
record
gener
informa
pharmaproject
databas
chronolog
order
market
approv
antivir
drug
last
thirti
year
repres
fig
cumul
analysi
fdaapprov
antivir
time
interv
show
almost
linear
progress
approv
per
year
fig
repres
roughli
onetenth
yearli
fda
approv
across
indic
http
wwwfdagovdownloadsaboutfdatranspar
detail
inspect
number
antivir
agent
approv
per
year
reveal
two
discret
wave
first
correspond
emerg
hiv
therapeut
peak
second
correspond
antihepat
c
viru
hcv
drug
fig
approv
period
indic
singl
largest
share
antivir
agent
approv
fig
indic
next
largest
share
approv
hcv
interv
combin
hcv
therapeut
account
twothird
antivir
drug
approv
fig
c
eleven
eight
drug
approv
treat
herpesvirida
cytomegaloviru
cmv
herp
simplex
viru
hsv
hbv
infect
respect
final
four
drug
approv
treat
extern
genit
wart
associ
human
papilloma
viru
hpv
infect
taken
togeth
drug
approv
treat
chronic
viral
infect
repres
antivir
approv
last
year
respect
acut
infect
five
drug
approv
treat
respiratori
virus
four
treatment
influenza
infect
one
respiratori
syncyti
viru
rsv
small
molecul
repres
domin
class
antivir
approv
total
antivir
larg
molecul
approv
period
fig
includ
five
uniqu
interferon
one
monoclon
antibodi
one
peptid
one
oligonucleotid
first
larg
molecul
approv
antivir
therapi
interferon
intron
mixtur
human
interferon
alpha
protein
use
treat
extern
genit
wart
associ
hpv
sinc
suppl
differ
form
recombin
interferon
subsequ
approv
interferon
alpha
alferon
n
also
treat
hpvassoci
infect
interferon
infergen
first
hcv
therapeut
interferon
introduc
soon
approv
peginterferon
pegintronsylatron
peginterferon
pegasi
antivir
monoclon
antibodi
palivizumab
synagi
approv
prophylact
treatment
infant
risk
contract
sever
rsv
infect
amino
acid
peptid
enfuvirtid
fuzeon
receiv
fda
approv
treatment
infect
salvag
therapi
approv
antivir
oligonucleotid
fomivirsen
vitraven
antisens
antivir
drug
use
treat
cytomegaloviru
cmv
induc
retin
immunocompromis
patient
monoand
combin
therapi
although
combin
therapi
wide
use
antimicrobi
anticanc
treatment
concept
combin
therapi
origin
pioneer
antiretrovir
treatment
main
purpos
combin
therapi
prevent
delay
emerg
drug
resist
inhibit
viral
replic
multipl
point
viral
life
cycl
period
antivir
monotherapi
approv
total
combin
therapi
approv
total
fig
approv
initi
combin
therapi
infect
follow
approv
individu
compon
monotherapi
help
explain
later
emerg
combin
drug
therapi
approv
fig
lamivudin
zidovudin
combivir
first
fixeddos
combin
therapi
approv
hivinfect
patient
soon
approv
lamivudin
fig
hcv
combin
therapi
nme
approv
part
combin
therapi
without
prior
individu
drug
approv
one
notabl
except
sofosbuvir
sovaldi
approv
first
monotherapi
hcv
approv
soon
combin
therapi
harvoni
epclusa
vosevi
fig
tabl
last
thirti
year
thirteen
antivir
drug
approv
ten
nme
target
host
mechan
approv
antivir
work
virustarget
directact
agent
interact
viral
target
fig
approv
hosttarget
molecul
includ
interferon
immunomodul
agent
interferon
interferon
interferon
peginterferon
peginterferon
five
hosttarget
small
molecul
approv
imiquimod
aldara
tolllik
receptor
tlr
agonist
approv
topic
treatment
genit
perian
wart
superfici
basal
cell
carcinoma
actin
keratosi
docosanol
abreva
approv
topic
cream
treat
herp
labiali
caus
infect
although
mechan
action
docosanol
entir
understood
broad
antivir
spectrum
interact
plasma
membran
suggest
act
directli
viral
particl
leung
sack
ribavirin
rebetol
guanosin
analog
approv
treatment
hcv
infect
ribavirin
believ
multipl
mechan
action
includ
immunomodul
inhibit
human
dehydrogenas
impdh
paeshuys
et
al
maraviroc
selzentri
approv
treat
infect
target
cc
chemokin
receptor
type
one
main
host
chemokin
receptor
viru
entri
tcell
topic
sinecatechin
veregen
water
extract
green
tea
leav
approv
treatment
genit
wart
caus
hpv
without
welldefin
mechan
action
therapi
approv
uniqu
nme
nme
classifi
target
either
viral
tabl
drug
name
abbrevi
use
criteria
describ
section
drug
approv
shown
blue
influenza
drug
approv
red
hbv
drug
approv
grey
cmv
hsv
drug
approv
green
approv
drug
indic
yellow
interpret
refer
color
figur
legend
reader
refer
web
version
articl
polymeras
proteas
integras
nonstructur
protein
act
host
exampl
antivir
drug
fall
classif
includ
fomivirsen
vitraven
antisens
oligonucleotid
oseltamivir
tamiflu
influenza
viru
neuraminidas
inhibitor
viral
enzym
polymeras
proteas
integras
repres
main
protein
target
antivir
agent
inhibitor
viral
enzym
account
twothird
antivir
includ
virusand
hosttarget
agent
approv
fig
approv
nme
polymeras
inhibitor
repres
largest
class
virustarget
agent
fig
polymeras
inhibitor
fall
two
categori
nucleosid
analog
nonnucleosid
inhibitor
although
zidovudin
retrovir
first
nucleosid
analog
approv
treatment
nucleosid
analog
use
virustarget
antimetabolit
acyclovir
zovirax
hsv
alreadi
approv
nucleosid
analog
prodrug
mimic
natur
nucleosid
use
triphosph
form
substrat
synthesi
viral
nucleic
acid
mean
nucleosid
analog
must
substrat
viral
polymeras
also
need
recogn
phosphoryl
host
nucleo
st
ide
kinas
longterm
use
firstgener
antihiv
nucleosid
analog
zalcitabin
hivid
didanosin
videx
limit
acut
toxic
due
insuffici
select
viral
human
dna
polymeras
johnson
et
al
secondgener
hivnucleosid
lamivudin
epivir
emtricitabin
emtriva
tenofovir
disoproxil
fumar
viread
display
greater
select
toler
nonnucleosid
polymeras
inhibitor
typic
bind
alloster
pocket
distinct
enzym
activ
site
antihiv
compound
nevirapin
viramun
becam
first
nonnucleosid
polymeras
inhibitor
receiv
fda
approv
sinc
four
nonnucleosid
polymeras
inhibitor
approv
treatment
delavirdin
mesyl
rescriptor
efavirenz
sustiva
etravirin
intel
rilpivirin
hydrochlorid
edur
sluiscrem
dasabuvir
exviera
current
nonnucleosid
polymeras
inhibitor
approv
treatment
hcv
infect
approv
nme
proteas
inhibitor
repres
second
preval
class
antivir
polymeras
inhibitor
proteas
inhibitor
block
essenti
matur
step
polyprotein
process
common
mani
virus
involv
viral
proteas
ten
proteas
inhibitor
commerci
saquinavir
mesyl
inviras
indinavir
sulfat
crixivan
ritonavir
norvir
nelfinavir
mesyl
viracept
amprenavir
ageneras
fosamprenavir
calcium
lexiva
lopinavir
kaletra
atazanavir
reyataz
tipranavir
aptivu
darunavir
prezista
lv
et
al
first
proteas
inhibitor
saquinavir
inviras
result
peptidomimet
design
approv
combin
ritonavir
boost
recent
approv
proteas
inhibitor
atazanavir
darunavir
aim
increas
potenc
bioavail
reduc
potenti
side
effect
experienc
firstgener
drug
class
seven
inhibitor
target
hcv
proteas
approv
includ
boceprevir
victr
grazoprevir
zepati
paritaprevir
viekira
pak
simeprevir
olysio
telaprevir
incivek
voxilaprevir
vosevi
glecaprevir
mavyret
fig
firstgener
inhibitor
boceprevir
telaprevir
approv
prescrib
alongsid
pegyl
interferon
ribavirin
potent
bettertoler
proteas
inhibitor
later
approv
combin
allor
interferonfre
regimen
act
genotyp
becom
bestinclass
wide
use
mccauley
rudd
integras
inhibitor
repres
third
major
class
therapeut
integras
inhibitor
block
integr
hiv
genom
viral
integras
human
chromosom
dna
three
integras
inhibitor
current
approv
raltegravir
isentress
elvitegravir
vitekta
dolutegravir
sodium
tivicay
raltegravir
elvitegravir
approv
respect
firstgener
integras
inhibitor
partial
overlap
resist
mutat
profil
fig
dolutegravir
secondgener
integras
inhibitor
display
higher
genet
barrier
resist
retain
antivir
potenc
raltegravirelvitegarvirdomin
escap
mutat
anstett
et
al
unlik
previous
describ
viral
drug
target
direct
act
agent
hcv
nonstructur
protein
enzymat
activ
dimer
membran
protein
interact
viral
rna
nonstructur
protein
make
essenti
hcv
replic
ledipasvir
harvoni
daclatasvir
dihydrochlorid
daklinza
first
inhibitor
receiv
fda
approv
fig
soon
follow
approv
ombitasvir
viekira
pak
velpatasvir
epclusa
pibrentasvir
mavyret
elbasvir
zepati
inhibitor
share
similar
bind
site
exquisit
vitro
antivir
potenc
picomolar
rang
translat
impress
viral
load
reduct
cure
rate
patient
gao
et
al
chang
trend
compar
approv
drug
januari
total
activ
drug
candid
activ
develop
span
phase
phase
phase
human
clinic
trial
fig
clinicalstag
drug
candid
program
target
hiv
hbv
hcv
tabl
increas
focu
toward
respiratori
infect
support
compound
evalu
treat
influenza
rsv
infect
respect
although
virustarget
agent
continu
domin
clinic
landscap
number
candid
hosttarget
mechan
increas
significantli
approv
antivir
antivir
clinic
candid
fig
similarli
small
molecul
continu
repres
major
class
antivir
candid
although
net
increas
number
biolog
oligonucleotid
candid
occur
rel
approv
antivir
drug
final
larg
major
antivir
clinic
candid
develop
monotherapeut
agent
rather
combin
therapi
could
simpli
result
surg
new
indic
evalu
rsv
dengu
smallpox
new
mechan
action
exploit
intervent
firstinclass
molecul
develop
case
firstinclass
therapi
approv
first
monotherapi
combin
agent
adher
remain
problem
combin
antiretrovir
therapi
requir
lifelong
daili
oral
medic
lack
adher
result
suboptim
drug
exposur
develop
viral
mutat
associ
drug
resist
address
limit
three
inject
longact
antiretrovir
clinic
develop
altern
daili
oral
regimen
jacobson
flexner
margoli
boffito
addit
efda
clinicalstag
nucleosid
revers
transcriptas
inhibitor
nrti
extrem
long
halflif
compat
weekli
oral
even
monthli
parenter
dose
reformul
rilpivirin
cabotegravir
intramuscular
nanoparticl
deliveri
also
provid
pharmacokinet
coverag
allow
longact
weekli
inject
tabl
anoth
signific
evolut
hiv
therapeut
intens
effort
toward
evalu
entri
inhibitor
fostemsavir
small
molecul
block
attach
tcell
broadli
neutral
monoclon
antibodi
also
current
consid
entri
inhibitor
caskey
et
al
experiment
drug
includ
ibalizumab
pro
share
similar
mechan
consist
prevent
viru
attach
receptor
although
util
novel
antivir
remain
fulli
defin
broadli
neutral
antibodi
could
provid
altern
current
oral
treatment
also
may
open
door
longact
regimen
extend
halfliv
gene
therapi
also
evalu
clinic
new
gener
hiv
therapeut
dual
therapeut
lentivir
vector
downregul
express
transduc
cell
via
rna
interfer
rnai
also
target
goal
control
hiv
infect
singl
treatment
burk
et
al
sb
blue
proteas
orang
integras
grey
nonstructur
protein
yellow
mechan
green
hosttarget
agent
red
defin
nme
drug
contain
activ
moieti
never
approv
fda
market
us
interpret
refer
color
figur
legend
reader
refer
web
version
articl
use
zincfing
base
nucleas
approach
edit
gene
alter
correspond
receptor
make
correspond
autolog
tcell
resist
hiv
infect
teba
et
al
tabl
multipl
novel
therapeut
approach
evalu
effort
find
effect
therapi
manag
cure
chronic
hepat
b
includ
exampl
hepat
b
surfac
antigen
hbsag
blocker
neutral
hbv
human
immunoglobulin
peptid
hepalatid
addit
rep
phosphorothio
oligonucleotid
target
hbsag
releas
tabl
fung
et
al
silenc
oligonucleotid
target
hbv
mrna
also
progress
phase
proofofconcept
studi
one
clinic
program
focus
target
hostbas
protein
bile
acid
regul
farnesoid
x
receptor
fxr
synthet
fxr
agonist
capsid
assembl
modul
cam
repres
major
class
novel
hbv
inhibitor
cam
current
clinic
trial
evalu
tabl
viral
capsid
form
core
protein
multipl
function
hbv
replic
cam
acceler
kinet
core
oligomer
prevent
encapsid
polymerasepregenom
rna
result
genomefre
capsid
reduct
coval
close
circular
dna
cccdna
berk
et
al
dual
mode
action
believ
differenti
previous
approv
nucleosid
analog
may
key
achiev
higher
function
cure
rate
given
alon
combin
current
standard
care
chronic
hbv
infect
often
result
weak
absent
virusspecif
tcell
reactiv
phenomenon
better
understood
refer
tcell
exhaust
ye
et
al
immunotherapi
provid
novel
approach
counteract
tcell
exhaust
enhanc
clearanc
hbvinfect
cell
iniragivir
sb
dinucleotid
phase
clinic
trial
claim
induc
interferon
signal
pathway
bind
cellular
protein
retino
acidinduc
gene
rigi
nucleotidebind
oligomer
domaincontain
protein
tabl
sinc
tlr
stimul
also
mediat
type
interferon
signal
agonist
rg
current
evalu
treatment
chronic
hbv
infect
continu
next
page
need
new
therapeut
option
influenza
viru
remain
high
despit
exist
vaccin
antivir
novel
polymeras
inhibitor
current
latestag
clinic
develop
nucleosid
analog
favipiravir
avigan
approv
japan
treatment
influenza
infect
limit
case
antiflu
drug
ineffect
knowledg
indic
favipiravir
current
develop
unit
state
elsewher
baloxavir
marboxil
pimodivir
phase
studi
unit
state
januari
target
polymeras
acid
pa
polymeras
basic
subunit
influenza
viru
polymeras
respect
tabl
compound
prevent
viru
hijack
host
cap
mrna
block
transcript
viral
gene
emerg
rsv
inhibitor
clinic
pipelin
justifi
year
unsuccess
vaccin
attempt
combin
high
medic
need
unaddress
palivizumab
prophylact
treatment
highrisk
infant
current
three
class
rsv
inhibitor
clinic
develop
secondgener
monoclon
antibodi
repres
first
class
rsv
inhibitor
recombin
monoclon
antibodi
modifi
fc
region
extend
halflif
develop
rsv
prophylaxi
infant
griffin
et
al
trival
nanobodi
target
rsv
fusion
f
protein
deliveri
via
inhal
detal
et
al
fusion
inhibitor
second
class
novel
rsv
inhibitor
block
essenti
conform
chang
rsv
f
protein
therebi
inhibit
cell
entri
prevent
fusion
viru
envelop
hostcel
membran
royman
et
al
current
fusion
inhibitor
includ
presatovir
tabl
replic
inhibitor
repres
third
class
rsv
drug
candid
lumicitabin
bind
polymeras
l
subunit
deval
et
al
coat
et
al
wherea
interfer
nucleoprotein
n
lumicitabin
current
rsv
replic
inhibitor
demonstr
clinic
proofofconcept
efficaci
devincenzo
et
al
recent
ebola
viru
outbreak
west
africa
trigger
intens
effort
identifi
novel
inhibitor
filovirus
favipiravir
two
nucleosid
analog
broad
spectrum
activ
consid
treatment
ebola
viru
diseas
longer
clinic
develop
sissoko
et
al
zmapp
combin
human
antibodi
produc
geneticallymodifi
tobacco
plant
target
ebola
glycoprotein
epitop
zmapp
test
clinic
west
africa
ebola
outbreak
although
zmapp
seem
benefici
result
meet
statist
signific
efficaci
group
et
al
new
research
develop
effort
also
result
identif
nucleotid
analog
polymeras
inhibitor
broad
antivir
spectrum
activ
follow
phase
safeti
studi
first
given
two
patient
one
unit
kingdom
octob
one
guinea
follow
month
compassion
use
request
jacob
et
al
dornemann
et
al
current
phase
studi
aim
evalu
antivir
efficaci
day
given
intraven
male
ebola
viru
diseas
survivor
shed
ebola
viru
semen
tabl
current
drug
approv
treatment
dengu
viru
infect
modipaf
celgosivir
current
phase
clinic
trial
treatment
adult
dengu
infect
present
within
h
fever
onset
modipav
antagonist
activ
plateletactiv
factor
receptor
pafr
host
protein
believ
implic
pathogenesi
sever
dengu
infect
inflamm
celgosivir
deriv
natur
product
also
hosttarget
agent
inhibit
alphaglucosidas
need
fold
viral
glycoprotein
two
compound
select
clinic
develop
safeti
previous
demonstr
human
inhibit
dengu
viru
replic
vitro
improv
surviv
lethal
mous
efficaci
model
souza
et
al
rathor
et
al
develop
smallpox
inhibitor
ration
need
stockpil
agent
aim
contain
potenti
futur
biothreat
brincidofovir
lipidconjug
prodrug
cidofovir
acycl
nucleosid
analog
broad
antivir
spectrum
dna
rna
virus
brincidofovir
current
clinic
evalu
treatment
smallpox
infect
biodefens
applic
phase
treatment
adenoviru
pediatr
stem
cell
transplant
recipi
brincidofovir
develop
smallpox
fda
anim
rule
allow
test
investig
drug
anim
model
support
effect
diseas
ethic
feasibl
studi
human
tecovirimat
also
develop
smallpox
anim
rule
smallpox
biodefens
applic
tecovirimat
identifi
via
highthroughput
screen
small
molecul
chemic
librari
shown
protect
nonhuman
primat
smallpox
infect
mucker
et
al
tecovirimat
inhibit
viral
protein
involv
virul
factor
format
envelop
virion
although
discoveri
antivir
drug
uniqu
stori
distinct
circumst
may
appli
program
section
aim
identifi
guidelin
exampl
attribut
drive
success
identifi
develop
antivir
drug
breakthrough
basic
biolog
biochem
scienc
lead
acceler
antivir
research
provid
springboard
drug
discoveri
applic
strike
exampl
establish
robust
cell
cultur
surrog
system
hcv
replic
although
hcv
first
isol
identifi
attempt
grow
viru
cell
cultur
unsuccess
greatli
limit
abil
evalu
novel
antivir
therapi
ten
year
research
need
develop
subgenom
replicon
system
captur
function
nonstructur
protein
recapitul
intracellular
step
viral
genom
replic
review
kaul
et
al
hcv
replicon
use
extens
primari
screen
antivir
test
establish
cell
cultur
system
key
discoveri
current
hcv
direct
act
agent
particularli
true
case
biochem
structur
biolog
tool
avail
assist
medicin
chemistri
effort
discoveri
daclatasvir
first
approv
hcv
inhibitor
result
highthroughput
screen
use
hcv
replicon
assay
belema
meanwel
target
phenotyp
screen
becom
major
contributor
understand
novel
mechan
inhibit
lead
differenti
antivir
program
flu
inhibitor
pimodivir
identifi
use
phenotyp
screen
condit
high
multipl
infect
moi
oseltamivir
activ
target
screen
approach
key
differenti
novel
inhibitor
larg
moi
independ
class
antiflu
agent
prevent
viru
replic
earli
stage
infect
byrn
et
al
fluoresc
microscopi
also
use
conjunct
highthroughput
screen
identifi
phenotyp
chang
associ
antivir
effect
nucleozin
preclin
firstinclass
influenza
inhibitor
first
character
abil
block
nuclear
accumul
nucleoprotein
infect
cell
kao
et
al
consid
grow
use
highcont
imag
antivir
test
mudhasani
et
al
watterson
et
al
like
target
phenotyp
screen
earli
access
mechan
action
inform
increasingli
import
role
antivir
drug
discoveri
exampl
also
show
mani
case
discoveri
firstinclass
antivir
drug
root
biolog
innov
ingeni
use
novel
vitro
assay
analysi
antivir
drug
approv
last
year
reveal
mani
exampl
bestinclass
program
follow
approv
drug
advanc
clinic
candid
detail
earlier
review
eg
polymeras
proteas
inhibitor
secondor
thirdgener
hiv
hcv
small
molecul
therapeut
led
bestinclass
drug
approv
provid
foundat
current
standard
care
case
research
program
tend
leverag
biolog
advanc
made
firstinclass
prototyp
molecul
focu
chemic
innov
followon
backup
approach
schulz
ringel
differ
strategi
use
foster
bestinclass
innov
small
molecul
sometim
reli
competit
intellig
ie
patent
bust
case
bestinclass
fastfollow
antivir
program
result
intensifi
medicin
chemistri
effort
aim
address
shortcom
firstgener
drug
intrins
bind
inhibit
potenc
straingenotyperesist
mutat
potenc
coverag
safeti
conveni
exampl
antihcv
drug
sofosbuvir
monophosph
nucleosid
prodrug
followon
firstgener
molecul
mericitabin
sofosbuvir
design
improv
metabol
activ
lead
higher
liver
triphosph
format
evad
first
limit
kinas
phosphoryl
step
murakami
et
al
similarli
drug
etravirin
design
overcom
suboptim
potenc
drug
resist
mutat
associ
firstgener
nonnucleosid
revers
transcriptas
inhibitor
da
et
al
latter
case
xray
crystallographi
revers
transcriptas
target
provid
valuabl
inform
structurebas
drug
design
approach
fragment
screen
expans
campaign
also
contribut
discoveri
novel
chemic
start
point
aim
identifi
nextgener
antivir
exampl
crystallograph
fragment
screen
hiv
integras
binder
recent
led
discoveri
novel
alloster
inhibitor
protein
target
gener
structur
biolog
proven
valuabl
tool
antivir
research
optim
ligand
effici
therefor
improv
potenc
inhibitor
interact
welldefin
molecular
target
one
main
challeng
develop
antivir
medicin
target
acut
viral
infect
limit
time
window
therapeut
intervent
may
greatli
fluctuat
depend
viru
patient
popul
mode
action
drug
candid
particularli
problemat
firstinclass
drug
candid
target
novel
therefor
clinic
unproven
target
pathway
enorm
obstacl
antivir
develop
partli
address
introduct
human
challeng
studi
commonli
use
earli
rsv
influenza
clinic
program
obtain
first
proofofconcept
efficaci
healthi
volunt
help
design
subsequ
clinic
trial
natur
infect
patient
bagga
et
al
healthi
adult
volunt
typic
infect
low
quantiti
viru
inoculum
control
condit
result
mild
symptom
human
challeng
studi
critic
clinic
develop
firstinclass
rsv
fusion
polymeras
inhibitor
presatovir
lumicitabin
respect
devincenzo
et
al
devincenzo
et
al
anoth
clinic
innov
antivir
research
increas
use
combin
therapi
hcv
therapeut
fig
made
possibl
avail
singl
agent
nonoverlap
mechan
action
addit
synergist
potenti
gradual
evolut
toward
bestinclass
combin
singletablet
regimen
use
combin
therapi
repres
anoth
major
clinic
innov
aim
increas
efficaci
adher
longterm
treatment
regimen
comparison
therapi
requir
two
pill
per
day
oncedaili
singletablet
regimen
associ
greater
adher
fewer
hospit
lower
overal
health
care
cost
cohen
et
al
consid
recent
surg
firstinclass
hbv
drug
candid
novel
mechan
action
evalu
drug
candid
potenti
combin
treatment
expect
likewis
excit
consid
novel
combin
treatment
respiratori
virus
given
recent
advanc
novel
monotherapi
target
influenza
rsv
phase
studi
pimodivir
combin
oseltamivir
demonstr
signific
reduct
viral
load
adult
influenza
http
wwwjnjcommediacenterpressreleasespimodiviraloneorincombinationwithoseltamivirdemonstratedasignificantreductioninvir
loadinadultswithinfluenzaa
final
establish
nation
program
organ
nation
institut
allergi
infecti
diseas
niaid
instrument
systemat
effici
recruit
elig
patient
new
experiment
treatment
summari
analysi
last
year
antivir
drug
approv
unit
state
demonstr
major
target
chronic
infect
caus
hbv
hcv
herpesvirus
hsv
cmv
drug
approv
treat
acut
infect
mainli
influenza
larg
major
approv
small
molecul
virustarget
agent
larg
molecul
hosttarget
therapi
high
rate
combin
therapi
approv
last
five
year
attribut
rich
hcv
drug
pipelin
reach
matur
multipl
therapeut
option
compet
bestinclass
molecul
contrast
molecul
current
clinic
develop
evalu
monotherapi
firstinclass
experiment
therapi
indic
lack
therapeut
option
fig
current
experiment
antivir
clinic
pipelin
also
reflect
least
partial
departur
classic
target
polymeras
oligonucleotidebas
therapeut
cell
fusion
inhibitor
capsidassembl
modul
array
novel
hostbas
mechan
addit
observ
surg
antihiv
broadli
neutral
monoclon
antibodi
reach
clinic
stage
evalu
current
antivir
clinic
pipelin
constantli
evolv
new
candid
enter
develop
clinic
program
termin
prepar
manuscript
us
fda
approv
biktarvi
bictegravir
emtricitabin
tenofovir
alafenamid
februari
treatment
infect
februari
xofluza
baloxavir
marboxil
receiv
japanes
regulatori
approv
use
influenza
infect
march
fda
approv
monoclon
antibodi
trogarzo
ibalizumab
heavili
treatmentexperienc
adult
hiv
patient
risk
fail
antiretrovir
therapi
author
declar
potenti
conflict
interest
respect
research
authorship
andor
public
articl
janssen
research
develop
provid
support
form
salari
author
addit
role
studi
design
data
collect
analysi
decis
publish
prepar
manuscript
